Achieving high-yielding, robust,
and reproducible chemistry is a prerequisite for the
18F-labeling of peptides for quantitative receptor imaging using positron emission tomography (PET). In this study, we extend the toolbox of oxime chemistry to include the novel prosthetic groups [
18F]-(2-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}ethoxy)acetaldehyde, [
18F]
5,
and [
18F]-4-(3-fluoropropoxy)benzaldehyde, [
18F]
9, in addition to the widely used 4-[
18F]fluorobenzaldehyde, [
18F]
12. The three
18F-aldehydes were conjugated to the same aminooxy-bearing RGD peptide
and the effect of the prosthetic group on biodistribution
and tumor uptake studied in mice. The peptide conjugate [
18F]
7 was found to possess superior
in vivo pharmacokinetics with higher tumor to blood, tumor to liver, tumor to muscle,
and tumor to lung ratios than either [
18F]
10 or [
18F]
13. The radioactivity from the [
18F]
7 conjugate excreted more extensively through the kidney route with 79%id passing through the urine
and bladder at the 2 h time point compared to around 55%id for the more hydrophobic conjugates [
18F]
10 and [
18F]
13. The chemical nature of a prosthetic group can be employed to tailor the overall biodistribution profile of the radiotracer. In this example, the hydrophilic nature of the ethylene glycol containing prosthetic group [
18F]
5 clearly influences the overall excretion pattern for the RGD peptide conjugate.